Back to Portfolio
HSIC

Henry Schein, Inc.

$77.45 8.9B market cap
Henry Schein, Inc. HSIC BUFFETT / MUNGER / KLARMAN SUMMARY
1 SNAPSHOT
Price$77.45
Market Cap8.9B
2 BUSINESS

Henry Schein is the world's largest dental and medical distributor -- a genuinely durable, scaled, low-margin business that David Einhorn increased +28% in Q1 2026 and that KKR has anchored with a ~$250M stake and two board seats. The bull case is a credible self-help turnaround: a brand-new CEO, a >$200M operating-income program, a mix shift toward higher-margin software and specialty manufacturing, and a buyback that has cut shares ~19% since 2020. The non-GAAP P/E of ~14.6x looks cheap. But the honest cash economics are mediocre -- ~$0.55-0.62B free cash flow on $13.2B revenue, 9.3% consolidated ROIC barely covering WACC, 12% ROE, ~$3.5B of debt against $3.2B equity, and a negative tangible book (no asset floor). My owner-earnings DCF lands at ~$66 versus a $77.45 price, so the market already pays for the turnaround. This is a fair business at a fair-to-full price, not a great business at a great price. WAIT for $60, get excited at $52.

3 MOAT NARROW

World's largest dental/medical distributor; overnight delivery density to hundreds of thousands of independent practices; primary distributor to most national DSOs; sticky practice-management software (Dentrix Ascend/Dentally); own-brand and specialty manufacturing.

4 MANAGEMENT
CEO: Fred Lowery

Mixed - disciplined ~3%/yr buyback engine, but historically funded with rising debt and executed at $77+ (above ~$66 intrinsic value); no dividend; serial acquirer of specialty/tech (goodwill now $4.2B).

5 ECONOMICS
5.75% Op Margin
9.3% ROIC
12.3% ROE
22.5x P/E
0.57B FCF
103% Debt/EBITDA
6 VALUATION
FCF Yield6.1%
DCF Range58 - 78

Overvalued by ~17% vs base intrinsic value of ~$66 (price sits between base and optimistic DCF).

7 MUNGER INVERSION
Kill Event Severity P() E[Loss]
Distribution disintermediation -- manufacturers/DSOs buying direct or e-commerce compressing the distributor's thin 5-6% operating spread, which has no cushion. HIGH - -
DSO consolidation shifting mix to lower-margin volume; leverage stress in a downturn; turnaround execution risk under a brand-new CEO. MED - -
8 KLARMAN LENS
Downside Case

Distribution disintermediation -- manufacturers/DSOs buying direct or e-commerce compressing the distributor's thin 5-6% operating spread, which has no cushion.

Why Market Right

Distribution disintermediation / e-commerce margin erosion; DSO consolidation degrading sales mix and margins; Leverage stress / refinancing at higher rates in a downturn

Catalysts

>$200M operating-income improvement program ($125M run-rate by end-2026, full by 2027); Mix shift to high-growth/high-margin businesses (>50% of operating income targeted by 2027); Aggressive buyback ($655M authorization remaining; ~3.2%/yr share reduction); KKR strategic partner + activist (Ananym) discipline; possible portfolio actions; New CEO Fred Lowery operational reset

9 VERDICT WAIT
B- Quality Moderate - net debt ~$3.35B (~2.9x adj EBITDA), interest expense up 5x since 2021; investment-grade but levered for a thin-margin business; no asset floor (negative tangible book).
Strong Buy$52
Buy$60
Fair Value$78

No position at $77.45 (~17% above $66 intrinsic value). Accumulate at $60, strong buy at $52. If accumulation triggers, size 1.5-2.5% (Tier 3 Adaptable).

🧠 ULTRATHINK Deep Philosophical Analysis

HSIC - Ultrathink Analysis

The Real Question

The stated question is "is Henry Schein cheap?" The real question is deeper and uncomfortable: what is the actual durable earnings power of a middleman whose entire reason for existing is that someone, somewhere, found it inconvenient to buy directly — and how much of that convenience premium survives a world of e-commerce, direct-to-DSO selling, and AI-optimized procurement?

Investing here is not a bet on dentistry. Dentistry is fine; people will keep getting cavities and implants and the aging population guarantees more procedures. It is a bet on the spread — the few cents of every dollar that flow to the company that warehouses the gauze and ships the burs overnight. That spread is 5.7 cents of operating margin on the dollar. The real question is whether that 5.7 cents is a fortress or a melting ice cube, and whether a new CEO with a private-equity partner can widen it faster than the world erodes it. Everything else — Einhorn's stake, the buyback, the non-GAAP P/E — is downstream of that single question.

Hidden Assumptions

The market (and the bull case) is making four assumptions that deserve to be dragged into the light:

  1. That non-GAAP earnings are real earnings. At 14.6x forward non-GAAP, HSIC looks cheap. But the $0.21B gap between GAAP and non-GAAP is largely amortization of intangibles the company paid cash for in its roll-up. If you bought it, it's a real cost. Free cash flow — the number that can't lie — says ~$0.55-0.62B, and that number reprices the stock from "cheap" to "fair."

  2. That the turnaround is incremental, not heroic. Management's >$200M operating-income program and "high-margin >50% by 2027" goal sound modest. But on a base of ~$0.76B GAAP operating income, $200M is a 26% improvement. That is not fine-tuning; that is a structural re-rating of a 40-year-old cost structure. The reverse DCF confirms the market already assumes ~5-6% perpetual owner-earnings growth — heroic relative to five years of ~1% revenue growth.

  3. That buybacks are automatically good. The share count fell 19% — a clean tailwind on the surface. But HSIC bought stock at $77+ (above my $66 intrinsic value) using rising debt. Repurchasing your own stock above fair value with borrowed money is the financial equivalent of paying retail with a credit card and calling it thrift.

  4. That a smart investor's purchase is a thesis. Einhorn bought and KKR anchored. The hidden assumption is that their conviction transfers. It doesn't. KKR's cost basis is ~$76.10 and its return math includes board influence, fee structures, and a multi-year horizon I don't share. Einhorn's thesis may be a 2-year event-driven turnaround trade, not a 10-year compounder hold. Borrowing someone else's conviction without their cost basis or their levers is how value investors get hurt.

The Contrarian View

For the bears to be completely right, this must be true: the distributor's role is structurally shrinking, not cyclically depressed. In that world, every manufacturer with scale (Straumann, Dentsply, Envista) sells more direct; every DSO large enough to matter builds its own procurement; Amazon Business and AI-driven ordering strip the "convenience" rationale from the long tail of independents; and HSIC's 29% gross margin grinds toward 26% as it fights to hold volume. On a 5.7% operating margin, a 3-point gross-margin loss is more than half of operating income gone. Layer on $3.5B of debt that must be refinanced at higher rates, and the equity — which has no tangible asset floor (negative tangible book) — can fall 50%+. The bear case is not "growth disappoints." The bear case is "the spread business is being disintermediated, and leverage turns a slow decline into a permanent impairment." I can state that bear case as well as any bear, which is precisely why I won't pay up.

Simplest Thesis

Henry Schein is a fair distribution business at a fair-to-full price — wait for $60, because at $77 you are pre-paying for a turnaround that hasn't shown up in the cash yet.

Why This Opportunity Exists

The mispricing — to the extent there is one — exists because the stock is a Rorschach test that different observers read with different rulers. The screen that flagged it "cheap" was reading forward non-GAAP (14.6x, cheap). The market that left it dead for five years was reading trailing GAAP (22x, dull) and five years of zero total return. Both are looking at the same company and seeing opposite things, and the gap between them is exactly the amortization-and-restructuring noise that a roll-up generates. This is a structural reason for confusion, not a temporary one — which is why the "value" could persist for years. The genuine new variable is the catalyst: a 40-year CEO finally leaving, an activist forcing the question, and KKR sitting on the board with a near-20% potential stake and a mandate to extract the latent margin. Opportunity exists here not because the market is dumb, but because the company is changing and nobody yet knows if the change works. That is an honest reason for a price near fair value — and an honest reason not to overpay for the outcome.

What Would Change My Mind

Concrete, falsifiable triggers that would move me from WAIT to BUY (independent of price):

  • Cash earnings inflect, not just non-GAAP. Free cash flow sustainably climbing through $0.75B (vs. the $0.55B five-year average) by FY2027 would prove the >$200M program is real and reprice my intrinsic value toward $80+.
  • Gross margin expands, not just holds. A move from 29% toward 31% would signal genuine pricing power and mix shift — converting the moat from "narrow/defensive" to "narrowing-no-more."
  • Deleveraging with buybacks bought below IV. Net-debt/EBITDA falling below 2.5x while repurchases happen under $65 would fix the capital-allocation knock and compound value fast.
  • Mix-shift proof. High-growth/high-margin businesses crossing 50% of operating income on schedule (2027).

Conversely, what confirms the bear and would make me reject, not just wait: gross margin below 28% for two consecutive years, or net income power still flat at ~$0.40-0.45B GAAP through FY2027 despite the program. That would mean the turnaround is a slide deck, not a business.

The Soul of This Business

The soul of Henry Schein is logistics intimacy. Strip away the segments and the acquisitions and what remains is a forty-year relationship with the dentist who, at 7am with a patient in the chair, needs a box of composite by tomorrow morning and trusts that one phone call (now one click) makes it appear. That trust — built over decades, dense across a continent, impossible to replicate quickly — is the real asset. It is why the business has survived and why it earns ~56% returns on its tangible operating capital.

But here is the essential tension that makes this a B- and not an A: that beautiful tangible-asset return is buried under $4.2B of goodwill the company paid to bolt on growth, dragging consolidated ROIC down to 9.3%. The soul of the operating business is excellent; the soul of the capital allocation is a serial acquirer that has spent its way to flat earnings power. The whole investment case reduces to whether the new regime — Lowery, KKR, the activist — refocuses the company on its excellent core and stops diluting it with mediocre M&A and over-priced debt-funded buybacks. If they do, the 56% tangible engine shows through and the stock is worth far more than $77. If they don't, it stays a fair business compounding at the speed of its own complexity. At $77 I can't tell which one I'm buying. At $60 I'd happily wait to find out.

Executive summary

Three-sentence thesis. Henry Schein is the world's largest distributor of products and services to office-based dental and medical practitioners — a genuinely durable, scaled, low-margin business that David Einhorn (Greenlight) increased +28% in Q1 2026 and that KKR has anchored with a ~$250M strategic investment and two board seats. The bull case is a self-help turnaround: a brand-new CEO (Fred Lowery, effective March 2, 2026), a >$200M operating-income improvement program, a fast-shrinking share count (down ~19% since 2020), and a non-GAAP P/E of ~14.6x that looks cheap. The problem is that the underlying business genuinely earns only ~$0.55-0.62B of free cash on $13.2B of revenue, has grown revenue ~1%/yr for five years, carries ~$3.5B of debt against $3.2B of equity, and my owner-earnings DCF lands at ~$66 — roughly 15% below today's price — so the market is already paying for the turnaround.

Verdict: WAIT. Quality grade B-. This is a fair business at a fair-to-full price, not a great business at a great price. The non-GAAP multiple flatters a company whose GAAP economics are mediocre (5.7% operating margin, 9.3% ROIC on a goodwill-laden balance sheet, 12% ROE). I want a margin of safety I do not get at $77. Accumulate below ~$60; strong buy below ~$52.

Key metrics dashboard

Metric Value Note
Revenue FY2025 $13.18B +4% YoY; ~1.2% 5yr CAGR
Gross margin 29.1% Stable; distribution economics
GAAP operating margin 5.75% Thin, typical for distribution
Non-GAAP operating margin (Q1'26) 7.53% +28bps YoY
GAAP net income FY2025 $0.40B Depressed by restructuring/amort
Non-GAAP EPS 2026E (guide) $5.23-5.37 Midpoint $5.30
FCF FY2025 $0.57B 5yr avg $0.545B
FCF yield (5yr avg) ~6.1% On market cap
ROE (FY2025) 12.3% Below Buffett 15% bar
ROIC (GAAP, incl. goodwill) 9.3% ~WACC; thin spread
ROIC (ex-goodwill, tangible) ~56% True operating asset return
Net debt ~$3.35B ~3.0x net-debt/adj-EBITDA
Dividend None All returns via buyback
Share count trend 143M (2020) -> 116M (Q1'26) -19% / -3.2% per yr

Phase 0 — Why does this opportunity exist? (Klarman)

The "cheap-looking" screen flag and the superinvestor signal both have identifiable, rational causes:

  1. GAAP optics distortion. Trailing-twelve-month GAAP EPS is ~$3.43 (P/E ~22x) because of restructuring charges, a 2024 goodwill/intangible impairment ($13M of a larger $73M restructuring), remeasurement gains/losses, and heavy amortization of acquired intangibles. On a non-GAAP basis (2026E EPS ~$5.30) the P/E is ~14.6x. Screens that read GAAP look pricey; screens that read forward non-GAAP look cheap. The truth is in between, and closer to "fairly valued."
  2. Five years of dead money. The stock has returned ~0.2% total over five years and ~2.9% over three years. The business has not grown earnings power; revenue is up ~1%/yr. Investors are bored and the multiple has compressed.
  3. 2023 cyberattack overhang. The October 2023 ransomware incident shut down North American and European dental/medical distribution for weeks, hit Q4 2023 results, and left a lingering impression of operational fragility and lost share. (Source: 10-K 2025, Risk Factors — "in October 2023 Henry Schein experienced a cybersecurity incident that primarily affected the operations of our North American and European dental and medical distribution businesses...disrupted key business operations, adversely impacted our financial results.")
  4. Activist + private-equity catalyst. Ananym Capital Management publicly pushed for board refresh, cost cuts, CEO succession, and a possible divestiture of medical distribution (Nov 2024). KKR then took an anchor stake — $250M at ~$76.10/share (May 2025), two board seats (Max Lin, William "Dan" Daniel), and a standstill cap raised from 14.9% to 19.9% in Nov 2025 (Strategic Partnership Agreement). This is the source of the "value-realization" thesis and likely what Einhorn is underwriting.

Note on the brief. The task referenced "Ares activist involvement." That is a misattribution. The actual actors are Ananym Capital (activist) and KKR (anchor investor / two board seats). No "Ares Management" appears in HSIC's 10-K or 2026 proxy. (Source: DEF 14A 2026; 10-K 2025.)

So the opportunity is real but understood: a flat, mediocre-return distributor that a credible activist + PE partner is trying to turn into a higher-margin, faster-buyback compounder. That is a "fixable operational problem + catalyst" setup — Klarman-legitimate — but it is not mispriced into the floor. The market already pays ~14.6x non-GAAP for the fix.

Phase 1 — Risk analysis (inversion)

"All I want to know is where I'm going to die, so I'll never go there." — Munger

How could this investment lose 50%+ permanently?

  1. Disintermediation of distribution. The central existential risk. If manufacturers (implant makers, consumable producers) and large DSOs (dental service organizations) increasingly buy direct, or if Amazon Business / e-commerce undercuts the "overnight delivery to hundreds of thousands of independent practices" value proposition, the thin 5-6% operating margin has no cushion. Distribution is a spread business; spreads compress permanently when the middleman's role erodes.
  2. DSO consolidation crushing the independent customer base. HSIC's economics are best with the long tail of independent practices (full-service, higher attach). As dentistry consolidates into DSOs that negotiate hard and sometimes self-distribute, mix shifts toward lower-margin, lower-attach volume. Q1 2026 already showed equipment growth "DSO-driven" with digital flat — a margin-mix warning.
  3. Leverage in a thin-margin business. Net debt ~$3.35B against ~$1.16B adjusted EBITDA is ~2.9x. That is manageable in good times but unforgiving if a second cyber event, a demand air-pocket, or a tariff/freight shock hits the 5.7% operating margin. Interest expense rose from $28M (2021) to $150M (2025) as debt funded acquisitions and buybacks.

Risk register

# Risk P(event over 5yr) Impact if occurs Expected loss Mitigant
1 Distribution disintermediation / e-commerce margin erosion 30% -35% -10.5% Own-brand mix, henryschein.com platform, DSO primary-distributor status
2 DSO consolidation degrades mix/margin 45% -20% -9.0% Primary distributor to most national DSOs; value-added services
3 Second major cyber incident 20% -25% -5.0% Post-2023 hardening; segmented systems
4 Turnaround/$200M program fails to land 40% -18% -7.2% New CEO, KKR oversight, back-half-weighted savings
5 Leverage stress in downturn (refi at higher rates) 25% -22% -5.5% Investment-grade profile, staggered maturities
6 Medical-distribution divestiture destroys value or distracts 25% -12% -3.0% Activist/PE discipline argues the opposite
Sum -40.2% (additive, non-correlated approximation)

Tail risk (non-additive). A recession that simultaneously (a) compresses elective-dentistry demand, (b) forces a refinancing at elevated rates, and (c) coincides with continued share loss to direct channels could mark equity down 50%+ given the operating and financial leverage stacked on a 5.7% margin. This is the scenario that makes me demand a real discount before buying.

Non-price sell triggers (pre-committed): (a) gross margin falls below ~28% for two consecutive years (disintermediation confirmed); (b) net-debt/EBITDA exceeds 3.5x without a clear deleveraging path; (c) the >$200M operating-income program is quietly abandoned or net income power stays flat through FY2027; (d) KKR exits or the activist thesis collapses without value realization.

Phase 2 — Financial analysis

Reality check on earnings power

This is the crux of the entire analysis. HSIC reports two very different pictures:

  • GAAP FY2025: revenue $13.18B, operating income $0.758B (5.75% margin), net income $0.398B, diluted EPS depressed by restructuring and intangible amortization.
  • Non-GAAP 2026 guide: diluted EPS $5.23-5.37 (~$0.61B net income), adjusted EBITDA ~$1.16B.

The $0.21B GAAP-to-non-GAAP gap is mostly (i) amortization of acquired intangibles from the specialty/technology roll-up and (ii) restructuring charges. Amortization of acquired intangibles is a real economic cost of a roll-up strategy (you paid cash for those intangibles), so I will not capitalize the full non-GAAP number. Free cash flow is the honest arbiter, and FCF has averaged $0.545B over five years and was $0.573B in FY2025. I set normalized owner earnings at **$0.62B** — slightly above 5yr-avg FCF to credit the maturing turnaround, well below the $0.61B non-GAAP NI + addbacks fantasy.

Returns: DuPont and ROIC

Year Net margin Asset turnover Leverage (A/E) ROE
2025 3.0% 1.18 3.46 12.3%
2024 3.1% 1.24 3.01 11.5%
2023 3.4% 1.17 2.89 11.4%
2022 4.3% 1.47 2.50 15.6%
2021 5.0% 1.46 2.48 18.2%

The decay is the story. ROE fell from ~18% (2021) to ~12% (2025), driven by margin compression (net margin 5.0% -> 3.0%) and rising leverage. The 2021 numbers were COVID-boosted (PPE, diagnostics, vaccine logistics). The cyberattack and the specialty/tech acquisition spree (more amortization, more debt) explain the rest.

  • ROIC (GAAP, including goodwill): 9.3%. NOPAT $0.583B / invested capital $6.27B. With a WACC of ~8-9%, the spread is roughly zero to slightly positive. A scaled distributor that barely out-earns its cost of capital on a consolidated basis is not a Buffett compounder.
  • ROIC ex-goodwill/intangibles: ~56%. The operating business (working capital + PP&E) earns extraordinary returns — distribution is asset-light on tangible capital. But HSIC has spent ~$4.2B of goodwill + ~$1.0B of intangibles buying growth, and those returns are diluted at the corporate level. The gap between 56% tangible ROIC and 9.3% all-in ROIC is the price of the roll-up. Whether future M&A earns its keep is the central capital-allocation question.

Owner earnings and valuation trinity

1) Liquidation / asset floor — there is none.

  • Tangible book value = equity $3.245B - goodwill $4.213B - intangibles $1.018B = -$1.99B (negative).
  • NCAV/share = (current assets $4.46B - total liabilities $6.42B)/115M = -$17/sh (negative).
  • There is no Graham asset floor. This is a going-concern, cash-flow story only.

2) Going-concern DCF (owner earnings $0.62B base).

Scenario OE growth (5yr) Terminal g Discount EV Equity value Per share
Bear 2% 2.0% 10% $7.9B $4.6B $40
Base 5% 2.5% 9% $10.9B $7.5B $66
Optimistic 6% 2.5% 8.5% $12.3B $9.0B $78
Bull 7% 3.0% 9% $12.6B $9.3B $81

3) Reverse DCF — what is priced in at $77.45? To justify today's EV of $12.25B on $0.62B owner earnings at a 9% discount rate, the market must believe HSIC compounds owner earnings at **5-6% for five years and ~2.5% in perpetuity.** That is a real acceleration from the ~1%/yr revenue and flat-earnings reality of the past five years. You are paying for the turnaround to succeed, with no margin of safety if it doesn't.

4) Multiple cross-checks.

  • EV/EBITDA: at 9-10x adjusted EBITDA ($1.16B), equity value is ~$62-72/sh. At 8x, ~$52/sh.
  • Owner earnings x12 = ~$36/sh; x15 = ~$52/sh (these understate because they ignore the EBITDA-to-OE wedge; I weight the DCF and EV/EBITDA more heavily).
  • Graham number (non-GAAP EPS $5.30, BVPS $28.22) = ~$58.

Intrinsic value estimate: ~$66 (weighting base DCF most heavily, EV/EBITDA 9-10x as corroboration, discounting the negative-asset-floor). Margin of safety at $77.45 is negative (-17%).

Margin of safety table

Method Value/share vs $77.45
Bear DCF $40 -48%
EV/EBITDA 8x $52 -33%
Graham number $58 -25%
EV/EBITDA 9-10x $62-72 -11% to -7%
Base DCF (IV) $66 -15%
Optimistic DCF $78 +1%
Bull DCF $81 +5%

The price sits between my base ($66) and optimistic ($78) cases — i.e., the market already credits a successful, above-history turnaround.

Phase 3 — Moat analysis

Moat: NARROW (cost-scale + density + modest switching), durable but not widening.

HSIC's competitive advantage is real and was earned over four decades, but it is the moat of an efficient distributor, not a brand or network monopoly.

Source Metric / evidence Durability
Scale & route density World's largest dental/medical distributor; overnight delivery to "hundreds of thousands of independent practices"; lowest cost-to-serve the long tail High — replicating national density is a decade-long capex problem for a rival
Primary-distributor lock-in Primary distributor to most national DSOs; integrated ordering, henryschein.com (>80% of US dental e-commerce on the platform) Moderate — DSOs have negotiating power and can multi-source
Switching friction Practice-management software (Dentrix Ascend, Dentally; cloud subs +25% YoY, >13,000 subscribers) embeds HSIC into the dentist's daily workflow Moderate-High in technology; the stickiest part of the business
Own-brand / corporate brand Higher-margin private label improving gross margin (+25bps YoY Q1'26) Moderate — a margin lever, not a moat by itself
Specialty manufacturing Owns implant/biomaterial brands (S.I.N., BioHorizons) — vertical integration into higher-margin product Moderate — competes with Straumann, Envista; premium implants flat-to-down

Will the moat be wider or narrower in 10 years? Probably about the same to slightly narrower. The distribution moat is structurally sound (density is hard to replicate) but faces two slow erosions: (1) e-commerce/direct compresses the distributor's take rate, and (2) DSO consolidation shifts power to large buyers. The offsetting widening force is technology: if HSIC successfully shifts mix toward software/SaaS and specialty manufacturing (management's stated goal: high-growth/high-margin businesses >50% of operating income by 2027), the blended moat strengthens and margins rise. This mix shift is the entire bull thesis — and it is unproven.

Pricing power test: gross margin is stable at ~29% and rose +25bps YoY in Q1'26 on own-brand mix and supplier cost work. That is defensive pricing power (hold margin), not offensive (raise it meaningfully). A wide moat raises price through cycles; HSIC mostly defends a thin spread. Hence narrow, not wide.

Phase 4 — Management and incentives

CEO transition (critical, recent). Stanley Bergman led HSIC for ~40 years and announced retirement July 2025. Fred Lowery became CEO effective March 2, 2026 — ~3 months in role at this analysis date. He is executing a "100-day plan," a "leaner, more agile Henry Schein," and the BOLD+1 strategy. (Source: DEF 14A 2026; Q1 2026 transcript.) A 40-year founder-CEO succession is itself a meaningful execution risk and a meaningful opportunity — new leadership with activist/PE pressure is exactly when latent margin is unlocked, or fumbled.

Activist + PE governance.

  • Ananym Capital (Nov 2024): pushed board refresh, cost cuts, CEO succession, possible medical-distribution divestiture.
  • KKR (Strategic Partnership Agreement, Jan 2025): $250M invested at ~$76.10/share (May 16, 2025; 3.285M shares); two board designees (Max Lin, William "Dan" Daniel); standstill cap raised 14.9% -> 19.9% (Nov 4, 2025). KKR can buy more in the open market up to the cap. (Source: 10-K 2025; DEF 14A 2026.)
  • This is constructive: a disciplined PE owner with two seats and a value-creation mandate, aligned with public shareholders through a near-20% potential stake.

Capital allocation. No dividend — all shareholder return is via buyback. Share count fell from 143.4M (2020) to 116.1M (Q1'26), ~19% / ~3.2% per year. Q1 2026: repurchased 1.6M shares at $77.64 avg ($125M), $655M authorization remaining. Caution: much of the buyback was funded by rising debt (net debt up while equity flat), and shares were repurchased at $77+ — above my $66 intrinsic value. Buying back stock above intrinsic value with borrowed money is value-destructive, not accretive. This is the single biggest mark against management's capital allocation, and a key thing the new CEO/KKR should fix.

Compensation (DEF 14A 2026). Former CEO Bergman's FY2025 total compensation was in the ~$10M range (base $1.707M + equity + incentive). Non-employee directors receive ~$200K cash retainers plus equity. Nothing egregious for a $9B company, but I want to see Lowery's package tied to ROIC/FCF/non-GAAP EPS rather than revenue — the proxy should be monitored next cycle.

Phase 5 — Catalysts

Catalyst Trigger Timeline Probability Impact
>$200M operating-income improvement program $125M run-rate by end-2026; full by 2027 12-24 mo 55% +15-25% if it lands
Mix shift to high-margin (>50% of op income by 2027) Technology + specialty growth 12-24 mo 50% +10-20% (re-rates multiple)
Continued aggressive buyback below IV $655M authorization Ongoing 70% +3-4%/yr if bought cheap
Medical-distribution divestiture / portfolio action Activist/KKR-driven 12-36 mo 30% Variable; could unlock or destroy value
New-CEO operational reset Lowery 100-day plan 6-18 mo — Re-rating if credible

The catalysts are genuine — this is not a value trap with no path. But they are operational self-help catalysts whose success is uncertain, and the price already discounts a fair amount of success.

Phase 6 — Decision synthesis

Expected-return probability tree (5-year horizon, from $77.45)

Scenario P 5yr price target Implied 5yr return Weighted
Bull (turnaround + re-rate to 17x, mix shift works) 20% $120 +55% +11.0%
Base (modest margin gains, buyback, multiple stable) 40% $90 +16% +6.4%
Stagnation (flat earnings, dead money continues) 25% $77 0% 0.0%
Bear (disintermediation/recession/leverage stress) 15% $45 -42% -6.3%
Expected 100% +11.1% total (~2.1%/yr)

A ~2%/yr expected return over five years from today's price is inadequate for the risk taken (operating + financial leverage on a thin-margin distributor with a goodwill-heavy balance sheet and no asset floor). At a lower entry the same tree produces a compelling return.

Entry prices

Level Price Basis
Strong buy $52 ~20% below base IV; EV/EBITDA ~8x; recession-resilient floor
Accumulate $60 ~10% below base IV; ~11x non-GAAP, ~6.5x EBITDA-adj entry
Fair value (IV) $66 Base DCF / EV-EBITDA midpoint
Current $77.45 ~17% above IV
Trim/exit $95+ >40% above IV; turnaround fully priced

Position sizing

WAIT — no position at $77.45. If accumulation begins at $60, size 1.5-2.5% (Tier 3 "Adaptable"): narrow moat, real catalyst, but thin margins, high leverage, and negative asset floor cap conviction.

Monitoring metrics

Metric Current Action threshold
Gross margin 29.1% <28% two years -> exit (disintermediation)
Net-debt/adj-EBITDA ~2.9x >3.5x -> de-risk
Non-GAAP operating margin 7.5% Stalls/falls through 2027 -> thesis break
High-margin % of op income ~50% <45% by 2027 -> mix-shift failing
Buyback price discipline $77+ avg Repurchasing >IV with debt -> red flag
FCF $0.57B Sustained <$0.45B -> earnings-power decay

Quality and tier

  • Quality grade: B-. Scaled, durable, cash-generative, but sub-cost-of-capital consolidated ROIC, 12% ROE, thin margins, heavy goodwill, no asset floor, elevated leverage.
  • Megatrend tier: T3 Adaptable. Demographics (aging population -> more dental/medical care) are a tailwind; AI/e-commerce is a two-edged disintermediation risk; protectionism/tariffs and freight are manageable headwinds; not a fortress.

Final recommendation

+---------------------------------------------------------------+
|                    INVESTMENT RECOMMENDATION                  |
+---------------------------------------------------------------+
| Company: Henry Schein, Inc.        Ticker: HSIC               |
| Current Price: $77.45    Date: 2026-06-06                     |
+---------------------------------------------------------------+
| VALUATION SUMMARY                                             |
|   Base DCF (owner earnings)      $66     -15% (no MOS)        |
|   EV/EBITDA 9-10x                $62-72  -11% to -7%          |
|   Graham number                  $58     -25%                |
|   Bear DCF                       $40     -48%                |
|   Tangible book / NCAV           negative  no asset floor     |
| INTRINSIC VALUE ESTIMATE: ~$66                                |
| MARGIN OF SAFETY at $77.45: -17% (price ABOVE value)         |
+---------------------------------------------------------------+
| RECOMMENDATION:  [ ] BUY  [ ] HOLD  [ ] SELL  [X] WAIT       |
+---------------------------------------------------------------+
| STRONG BUY:   $52   (~20% below IV, ~8x EBITDA)              |
| ACCUMULATE:   $60   (~10% below IV)                          |
| FAIR VALUE:   $66                                            |
| TRIM/EXIT:    $95+  (turnaround fully priced)               |
+---------------------------------------------------------------+
| POSITION SIZE: 0% now; 1.5-2.5% if accumulation triggers     |
| CATALYST: >$200M op-income program + KKR/activist value reset |
| PRIMARY RISK: Distribution disintermediation on a 5.7% margin |
| SELL TRIGGER: Gross margin <28% 2yr; net-debt/EBITDA >3.5x    |
+---------------------------------------------------------------+

Bottom line. Einhorn and KKR may well be right that there is latent margin and a buyback engine here, and the non-GAAP P/E of ~14.6x is the cheapest-looking thing about the stock. But the honest cash economics — ~$0.55-0.62B FCF, 9.3% consolidated ROIC, 12% ROE, ~$3.5B debt, no asset floor — produce a base intrinsic value near $66, and at $77 you are pre-paying for a turnaround that has not yet shown up in the numbers. Wait for $60, get excited at $52. No penalty for not swinging.

Sources

Document Source Key data extracted
10-K FY2025 (filed 2026-02-24) SEC EDGAR CIK 0001000228 Segments, cyber incident, KKR terms, share count (114.7M @ Feb 17 2026), risk factors, impairments
10-K FY2024 SEC EDGAR Prior-year balance sheet, restructuring
10-Q Q1 2026 (period ended 2026-03-28) SEC EDGAR Q1 shares 116.06M, debt $3.49B
DEF 14A 2026 (filed 2026-04-08) SEC EDGAR Bergman/Lowery succession, KKR Strategic Partnership Agreement, standstill 19.9%, director/exec comp
Income/Balance/Cash-Flow statements (6yr) AlphaVantage MCP Revenue, margins, debt, FCF, ROIC inputs
Historical daily prices (2020-2026) AlphaVantage MCP (EODHD token 401) $77.45 close, 52wk $62.03-$83.35, returns
Earnings transcript Q1 2026 AlphaVantage MCP Guidance ($5.23-5.37 EPS), segments, $200M program, buyback $125M
Earnings transcript Q4/FY2025 AlphaVantage MCP FY2025 results, strategy

Data caveat: the processed financial-summary.md shows EPS as $0.00 (script field-mapping gap) and a spurious "$2.10B dividend" in 2023 (cash-flow field-mapping artifact — HSIC has never paid a common dividend; that figure is buyback-related). All per-share, dividend, and return figures in this analysis were computed directly from the source JSON and filings, not from that summary.